NCT02105675View on ClinicalTrials.gov

Phase II Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

March 31, 2014

Study Completion Date

February 20, 2017

Conditions
Prostate CancerProstate Cancer Metastatic
Interventions
BIOLOGICAL

Dendritic Cells DCVAC/PCa

DCVAC/PCa is the experimental therapy added on to Docetaxel

DRUG

Docetaxel

Docetaxel is Standard of Care First Line Chemotherapy

Trial Locations (10)

Unknown

Brno

Hradec Králové

Jihlava

Liberec

Nová Ves pod Pleší

Olomouc

Ostrava

Prague

Ústí nad Labem

Zlín

All Listed Sponsors
lead

SOTIO a.s.

INDUSTRY

NCT02105675 - Phase II Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter